| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer (NCT05364645) | SWOG Cancer Research Network | 2022-07-25 |
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (NCT05334329) | University of California, Irvine | 2022-07-20 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (NCT05098210) | Fred Hutchinson Cancer Center | 2022-06-09 |
| Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT05096663) | SWOG Cancer Research Network | 2022-03-15 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (NCT04919369) | Dwight Owen | 2021-10-18 |
| Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (NCT04837716) | M.D. Anderson Cancer Center | 2021-03-18 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study (NCT05022394) | M.D. Anderson Cancer Center | 2021-02-18 |
| NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (NCT04505267) | M.D. Anderson Cancer Center | 2021-02-10 |
| Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer (NCT04533451) | Alliance for Clinical Trials in Oncology | 2020-11-16 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (NCT04250545) | National Cancer Institute (NCI) | 2020-10-26 |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer (NCT04479306) | M.D. Anderson Cancer Center | 2020-06-18 |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NCT04092283) | National Cancer Institute (NCI) | 2020-04-29 |
| Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (NCT04268550) | SWOG Cancer Research Network | 2020-04-08 |
| Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC (NCT04227028) | City of Hope Medical Center | 2020-03-09 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer (NCT04151940) | University of Washington | 2019-09-26 |
| Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) (NCT03971474) | SWOG Cancer Research Network | 2019-05-28 |
| Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT03845296) | SWOG Cancer Research Network | 2019-04-16 |
| Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer (NCT03581487) | M.D. Anderson Cancer Center | 2019-04-01 |
| Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (NCT03707938) | M.D. Anderson Cancer Center | 2018-12-18 |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer (NCT03600701) | National Cancer Institute (NCI) | 2018-11-29 |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (NCT03191149) | National Cancer Institute (NCI) | 2018-04-25 |
| Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced (NCT03225664) | M.D. Anderson Cancer Center | 2018-02-03 |
| Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study (NCT03410043) | M.D. Anderson Cancer Center | 2018-01-17 |
| Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT03132532) | Mayo Clinic | 2017-07-31 |
| Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer (NCT03110978) | M.D. Anderson Cancer Center | 2017-06-26 |
| Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer (NCT03050060) | University of Washington | 2017-06-09 |
| Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer (NCT02503722) | National Cancer Institute (NCI) | 2017-03-23 |
| Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (NCT03066206) | M.D. Anderson Cancer Center | 2017-03-17 |
| Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer (NCT02642042) | National Cancer Institute (NCI) | 2016-07-18 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663) | National Cancer Institute (NCI) | 2016-05-11 |
| Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT02535338) | National Cancer Institute (NCI) | 2016-04-11 |
| Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT01912625) | National Cancer Institute (NCI) | 2013-10-28 |
| Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT01708954) | National Cancer Institute (NCI) | 2013-02-13 |
| Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer (NCT01725165) | M.D. Anderson Cancer Center | 2012-11-28 |
| Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer (NCT01629498) | M.D. Anderson Cancer Center | 2012-09-17 |
| Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NCT01281124) | National Cancer Institute (NCI) | 2011-01-12 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery (NCT00254384) | M.D. Anderson Cancer Center | 2005-10-05 |